UBS AM Portfolio holdings
UBS Asset Management (UBS AM), a division of UBS Group AG with origins tied to the bank’s founding in 1862, is headquartered in Zurich, Switzerland, and manages hundreds of billions in assets for institutional, intermediary, and wealth management clients globally. Specializing in a broad range of investment strategies—including equities, fixed income, multi-asset, alternatives, and sustainable investing—UBS AM leverages the firm’s extensive research capabilities and global network to deliver tailored solutions. Known for its focus on risk management and innovation, it offers products like ETFs, index funds, and private market investments, catering to diverse needs from pension funds to high-net-worth individuals. As part of UBS’s broader ecosystem, UBS AM combines Swiss precision with a commitment to ESG principles, solidifying its position as a leader in the asset management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$25.3B |
| 2 |
Bank of America
BAC
|
+$1.96B |
| 3 |
Applied Materials
AMAT
|
+$1.43B |
| 4 |
NetEase
NTES
|
+$1.18B |
| 5 |
Union Pacific
UNP
|
+$870M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$7.17B |
| 2 |
Apple
AAPL
|
+$3.39B |
| 3 |
UBS Group
UBS
|
+$2.73B |
| 4 |
Alphabet (Google) Class A
GOOGL
|
+$2.53B |
| 5 |
Meta Platforms (Facebook)
META
|
+$2.04B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.88% |
| 2 | Financials | 12.37% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Healthcare | 9.66% |
| 5 | Communication Services | 9.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1726
Establishment Labs
ESTA
$1.76B
| $2.09M | ﹤0.01% |
51,103
-30,806
| -38% | -$1.26M |
2021 Q2
17 quarters
|
|
1727
TFS Financial
TFSL
$4.58B
| $2.09M | ﹤0.01% |
158,970
-76,443
| -32% | -$1.01M |
2013 Q2
49 quarters
|
|
1728
Cannae Holdings
CNNE
$688M
| $2.09M | ﹤0.01% |
113,895
-78,644
| -41% | -$1.55M |
2017 Q4
31 quarters
|
|
1729
Bank First Corp
BFC
$1.64B
| $2.08M | ﹤0.01% |
17,142
-10,718
| -38% | -$1.33M |
2020 Q3
20 quarters
|
|
1730
BrightView Holdings
BV
$976M
| $2.08M | ﹤0.01% |
155,039
-80,745
| -34% | -$1.2M |
2019 Q2
25 quarters
|
|
1731
CTS Corp
CTS
$1.57B
| $2.08M | ﹤0.01% |
52,016
-49,105
| -49% | -$2.04M |
2018 Q4
27 quarters
|
|
1732
United States Lime & Minerals
USLM
$3.04B
| $2.07M | ﹤0.01% |
15,703
-12,742
| -45% | -$1.47M |
2023 Q3
8 quarters
|
|
1733
Syndax Pharmaceuticals
SNDX
$1.15B
| $2.07M | ﹤0.01% |
134,261
-121,877
| -48% | -$1.6M |
2020 Q4
19 quarters
|
|
1734
Ducommun
DCO
$2.58B
| $2.06M | ﹤0.01% |
21,456
-24,618
| -53% | -$2.22M |
2022 Q4
11 quarters
|
|
1735
Phibro Animal Health
PAHC
$1.58B
| $2.06M | ﹤0.01% |
50,923
-39,734
| -44% | -$1.31M |
2021 Q1
18 quarters
|
|
1736
Apogee Enterprises
APOG
$865M
| $2.06M | ﹤0.01% |
47,166
-28,554
| -38% | -$1.23M |
2023 Q1
10 quarters
|
|
1737
Cogent Biosciences
COGT
$5.12B
| $2.05M | ﹤0.01% |
142,954
-64,244
| -31% | -$761K |
2022 Q4
11 quarters
|
|
1738
DELISTED
Vimeo
VMEO
| $2.05M | ﹤0.01% |
264,847
-227,329
| -46% | -$1.12M |
2021 Q2
17 quarters
|
|
1739
CareDx
CDNA
$3.31B
| $2.05M | ﹤0.01% |
140,919
-133,769
| -49% | -$1.91M |
2024 Q3
4 quarters
|
|
1740
DELISTED
BioLife Solutions
BLFS
| $2.05M | ﹤0.01% |
80,254
-11,608
| -13% | -$275K |
2020 Q4
19 quarters
|
|
1741
NETGEAR
NTGR
$599M
| $2.04M | ﹤0.01% |
63,085
-41,314
| -40% | -$1.13M |
2024 Q2
5 quarters
|
|
1742
Virtus Investment Partners
VRTS
$814M
| $2.04M | ﹤0.01% |
10,737
-9,690
| -47% | -$1.91M |
2017 Q1
34 quarters
|
|
1743
Ardelyx
ARDX
$798M
| $2.04M | ﹤0.01% |
370,109
-264,136
| -42% | -$1.43M |
2023 Q1
10 quarters
|
|
1744
Clover Health Investments
CLOV
$2.38B
| $2.03M | ﹤0.01% |
664,630
-437,179
| -40% | -$1.25M |
2024 Q3
4 quarters
|
|
1745
Simon Property Group
SPG
$66.5B
| $2.03M | ﹤0.01% |
10,824
-429,671
| -98% | -$74.2M |
2013 Q2
49 quarters
|
|
1746
Under Armour
UAA
$2.04B
| $2.03M | ﹤0.01% |
406,399
-243,683
| -37% | -$1.42M |
2013 Q2
49 quarters
|
|
1747
1st Source
SRCE
$2.07B
| $2.02M | ﹤0.01% |
32,859
-25,143
| -43% | -$1.58M |
2021 Q1
18 quarters
|
|
1748
Monarch Casino & Resort
MCRI
$2.04B
| $2M | ﹤0.01% |
18,905
-18,270
| -49% | -$1.83M |
2020 Q2
21 quarters
|
|
1749
Collegium Pharmaceutical
COLL
$755M
| $1.99M | ﹤0.01% |
57,016
-37,771
| -40% | -$1.31M |
2018 Q2
29 quarters
|
|
1750
Crescent Energy
CRGY
$5.82B
| $1.99M | ﹤0.01% |
223,296
-237,779
| -52% | -$2.16M |
2022 Q2
13 quarters
|
|
Similar funds
UBS AM's Q3 2025 Portfolio in Review
As of Q3 2025, UBS AM held 2,672 positions worth $461B, down 6.8% from $494B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
UBS AM withdrew a net $68.7B in Q3 2025, closing 403 positions and reducing 2,008 holdings. Its most notable exit was Pinduoduo, an estimated $967M position sold in full.
By sector, the portfolio is most concentrated in Technology at 38% of assets, up from 32% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, UBS AM opened a new position in Vanguard Dividend Appreciation ETF worth $135M.
- UBS AM's largest Q3 2025 buy was Vanguard Dividend Appreciation ETF: 624,303 shares worth $135M.
- UBS AM added most to Microsoft in Q3 2025, an estimated $25.3B increase.
- UBS AM's biggest Q3 2025 reduction was NVIDIA, cutting an estimated $7.17B.
- UBS AM fully exited Pinduoduo in Q3 2025, selling an estimated $967M.
- UBS AM's ten largest holdings make up 35% of its $461B portfolio in Q3 2025.
- UBS AM opened 67 new positions and closed 403 in Q3 2025.
- UBS AM's portfolio value fell 6.8% quarter-over-quarter to $461B.
Based on UBS AM's 13F filing for Q3 2025, filed 14 Nov 2025.